Skip to main content

Peer Review reports

From: Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

Original Submission
7 May 2015 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
12 Jun 2015 Editorially accepted
23 Jun 2015 Article published 10.1186/s12883-015-0354-9

You can find further information about peer review here.

Back to article page